MIR30C1

Summary

MIR30C1 (microRNA 30c-1, HGNC:31626) is a microRNA gene on chromosome 1p34.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407031 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31626
Approved symbol	MIR30C1
Name	microRNA 30c-1
Location	1p34.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-30c-1
Ensembl gene	ENSG00000207962
Ensembl biotype	miRNA
OMIM	615151
Entrez	407031
RNAcentral	URS000075D43C — miRNA, 89 nt, 32 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385227

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385227 — 1 exons

Exon	Start	End
ENSE00001500233	40757284	40757372

Expression profiles

Bgee: expression breadth broad, 31 present calls, max score 83.53.

Top tissues by expression

31 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	83.53	gold quality
heart	UBERON:0000948	79.80	gold quality
heart left ventricle	UBERON:0002084	76.80	gold quality
monocyte	CL:0000576	73.07	gold quality
stomach	UBERON:0000945	72.33	gold quality
calcaneal tendon	UBERON:0003701	72.05	gold quality
right lobe of liver	UBERON:0001114	71.30	gold quality
islet of Langerhans	UBERON:0000006	71.23	gold quality
corpus callosum	UBERON:0002336	71.08	gold quality
right adrenal gland	UBERON:0001233	70.85	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	70.70	gold quality
placenta	UBERON:0001987	69.76	gold quality
body of uterus	UBERON:0009853	67.67	gold quality
intestine	UBERON:0000160	67.37	gold quality
left adrenal gland	UBERON:0001234	66.45	gold quality
esophagus mucosa	UBERON:0002469	66.12	gold quality
body of stomach	UBERON:0001161	66.10	gold quality
thoracic mammary gland	UBERON:0005200	65.74	gold quality
left adrenal gland cortex	UBERON:0035825	65.73	gold quality
fallopian tube	UBERON:0003889	65.29	gold quality
skin of leg	UBERON:0001511	64.99	gold quality
lower esophagus muscularis layer	UBERON:0035833	64.95	gold quality
skin of abdomen	UBERON:0001416	64.47	gold quality
left ovary	UBERON:0002119	63.19	gold quality
small intestine Peyer’s patch	UBERON:0003454	61.33	gold quality
colon	UBERON:0001155	59.82	gold quality
vagina	UBERON:0000996	58.88	gold quality
lung	UBERON:0002048	57.88	gold quality
anterior cingulate cortex	UBERON:0009835	52.27	gold quality
right testis	UBERON:0004534	48.73	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.43

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• identified hsa-miRNA-30c as an independent predictor for clinical benefit of tamoxifen therapy in patients with advanced breast cancer (PMID:20490652)
• common variants in precursor microRNA (pre-miRNA) sequences play a role in the prediction of non-small cell lung cancer (NSCLC) survival (PMID:20889907)
• Expression analysis detected that rs928508 AA showed a significantly increased level of mature miR-30c compared with GG or AG/GG genotype (PMID:22108846)
• Data indicate that miR-30b/c and miR-21 target respectively the 3’ untranslated region of caspase-3 and TAp63 mRNAs. (PMID:22964638)
• MIR-30c plays a key role in radiation-induced cell damage through regulation of REDD1 expression. (PMID:23144934)
• The rs928508(A/G) polymorphism in flanking region of miR-30c could influence the processing from pri-miR-30c to mature miR-30c, but does not influence the transcription of pri-miR-30c. (PMID:23159078)
• these data suggest that miR-30C, a tumor suppressor miRNA, contributes to anti-cancer properties of sulfuretin by negatively regulating cyclin D1 and D2, providing important implications of sulfuretin and miR-30C for the therapeutic intervention of human cancers. (PMID:23318178)
• An interleukin-6 family member, interleukin-11 is identified as a secondary target of twinfilin 1 in the microRNA-30c signalling pathway. (PMID:23340433)
• hypoxia induces epithelial-mesenchymal transition in renal cell carcinoma cells through downregulation of miR-30c, which leads to subsequent increase of Slug expression and repression of E-cadherin production. (PMID:24112779)
• Hsa-miR-30b and hsa-miR-30c are negative regulators of cell death induced by loss of attachment through down-regulation of caspase 3 expression. (PMID:24129493)
• Crohn’s disease-associated adherent invasive Escherichia coli suppress the autophagy response to replicate within host cells by dysregulating miR-30c and miR-130a expression. (PMID:24148619)
• MYBL2 overexpression was associated with lower expression of miR-30a (P=0.024), miR-30b (P=0.021) and miR-30c (P=0.009). (PMID:24199710)
• Our data indicated the involvement of miR-30c in PCa progression and suggested its potential role as an independent predictor of biochemical recurrence in PCa. (PMID:24452717)
• MiR-30c is an important deregulated miRNA in endometrial cancer and might serve as a potential biomarker and novel therapeutic target for EC. (PMID:24595016)
• Overexpression of either miR-192 or miR-30c in enterocyte and hepatocyte cells suggested an effect on the expression of genes related to lipid metabolism. (PMID:24623846)
• validation of a class of serum miR-30c that could act as novel non-invasive biomarkers for diagnosis of Polycystic ovary syndrome (PCOS); miR-30c may be involved in the pathogenesis of PCOS. (PMID:24802714)
• Aberrant miR30c expression alters the expression levels of markers (Ecadherin, snail and vimentin) of epithelial mesenchymal transition. (PMID:25119247)
• we demonstrate that the expression pattern of FHIT and miR-30c is inversely correlated with that of MTDH and HMGA2 in normal tissue, non-metastatic and metastatic tumors, serving as a potential biomarker for metastasis in lung cancer. (PMID:25340791)
• Data indicate that combinations of microRNAs let-7c, miR-30c, miR-141, miR-375, and prostate-specific antigen (PSA) obtained better discrimination than PSA alone as noninvasive diagnostic biomarkers for screening of prostate cancer (PC). (PMID:25521481)
• miR-30c plays an important role in lipid metabolism, adipogenesis, and cell proliferation and differentiation. [Review] (PMID:25692340)
• MiR-331-3p and miR-30c were highly correlated with each other and not only explained Non-alcoholic fatty liver disease discordancy between twins but also were significantly different between participants with and without NAFLD. (PMID:26002934)
• We describe novel ABCC9 variants in human brain, corresponding to altered 3’UTR length, which could lead to targeting by miR-30c (PMID:26115089)
• Loss of miR-30c and miR-203a expression is a marker for the poor prognosis of HCC. (PMID:26210453)
• Mir-30c was described to target the pro-fibrotic growth factor CTGF in the myocardium, miR-30c predominantly expressed in cardiac fibroblasts. (PMID:26398116)
• the average survival times of low-hsa-miR-30c and high-hsa-miR-203 groups were significantly lower than those of the corresponding groups with the log-rank P of 0.015 and 0.023, respectively. In summary, our study suggested that both hsa-miR-203 and hsa-miR-30c are potential biomarkers for detection and prognosis of Prostate cancer (PMID:26499781)
• In conclusion, isolinderalactone induces apoptosis in MDA-MB231 cells and suppresses STAT3 signaling pathway through regulation of SOCS3 and miR-30c. (PMID:26707189)
• results not only identified miR-30c with the regulation effect on the activation and cytotoxicity of Natural Killer cells, but also suggested that microRNA molecules may play different roles in diverse systems (PMID:26968781)
• miR-30c-1-3p was shown to alter the expression of CYP3A4, a prototypical target gene of PXR. (PMID:27085140)
• miRNA-30c, a previously reported marker of blastocyst implantation potential, was significantly more abundant in spent blastocyst medium from twin embryos. (PMID:27612589)
• this study shows that expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva (PMID:27835588)
• urinary biomarker for ischemia-reperfusion-induced kidney injury (PMID:28056546)
• A feedback loop between miR-30a-5p/miR-30c-5p and DNMT1 is a potent signature for cisplatin-resistance and epithelial-mesenchymal transition in ovarian cancer. (PMID:28222434)
• Our study shows that genomic imbalances are involved in miR-30c and let-7a deregulation. One can reasonably assume that dysregulation of these miRNAs is a cause leading to HMGA2 upregulation in ovarian tumors. (PMID:28423547)
• our studies indicate that Curcumin increases the sensitivity of Paclitaxel-resistant non-small-cell lung cancer cells to Paclitaxel through microRNA-30c-mediated MTA1 reduction. Curcumin might be a potential adjuvant for non-small-cell lung cancer patients during Paclitaxel treatment. (PMID:28443468)
• A single G to A substitution present in the terminal loop of pri-mir-30c-1 directly affects Drosha-mediated processing of pri-mir-30c-1 in vitro and in cultured cells. Structural analysis of this variant revealed an altered RNA structure that facilitates the interaction with SRSF3, an SR protein family member that promotes pri-miRNA processing. (PMID:28466845)
• Identify miR-30c as a specific correlate of pulmonary manifestations of TB, potentially involved in the altered glucocorticoid sensitivity observed in these patients. (PMID:28610790)
• CTHRC1, negatively regulated by miR-30c, promoted cell proliferation, invasion and migration and suppressed cell apoptosis in breast cancer, which might be by activating GSK-3beta/beta-catenin signaling and inhibiting Bax/Caspase-9/Caspase-3 signaling respectively. (PMID:28697793)
• MiR-30c and MTA1 abnormally expressed in ovarian cancer (OC), which may be related to metastasis of OC. In MiR-30c as a tumor suppressor gene, its expression in OC could lead to reduced expression of MTA1, which may be one of the mechanisms of metastasis of OC cells. (PMID:28901313)
• Reduction of miR-30c-5p in microparticles as a promoter of early atherosclerosis, by conveying pro-inflammatory pro-apoptotic signals and impairing endothelial healing. (PMID:29016810)
• miR-30c could suppress giant cell tumor of bone cell proliferation and progression via HOXA1, which might provide a new target for giant cell tumor of bone diagnosis and therapy (PMID:29164581)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir30c-1	ENSMUSG00000065490

Paralogs (5): MIR30E (ENSG00000198974), MIR30C2 (ENSG00000199094), MIR30D (ENSG00000199153), MIR30B (ENSG00000207582), MIR30A (ENSG00000207827)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.